Parkinson's Disease Psychosis Clinical Trial
Official title:
A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson's Disease
To assess the long-term safety and tolerability of ACP-103 in subjects with Parkinson's disease psychosis.
This study did not have a fixed duration, and the duration of individual subject participation was determined based on investigator assessment of subject tolerability and continued benefit until such time as either the drug was commercially available in the US, or an alternate treatment extension was available in non-US regions. For this reason, no subjects, therefore, were considered to have "completed" the study. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06068465 -
A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis
|
Phase 3 | |
Recruiting |
NCT04373317 -
Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis
|
Phase 4 | |
Completed |
NCT01518309 -
An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients
|
Phase 2 | |
Completed |
NCT00658567 -
A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
|
Phase 3 | |
Completed |
NCT00477672 -
A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
|
Phase 3 | |
Completed |
NCT01174004 -
A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis
|
Phase 3 | |
Recruiting |
NCT05590637 -
Comparing Antipsychotic Medications in LBD Over Time
|
Phase 4 | |
Approved for marketing |
NCT02762591 -
Expanded Access of Pimavanserin for Patients With PD Psychosis
|
N/A |